Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists: Antithrombotic Agents in Atrial Fibrillation (ATA-AF) survey

Journal of Cardiovascular Medicine

Volumn 15, Issue 8, 2014, Pages 626-635

  Berisso, Massimo Zoni ^a   Fabbri, Gianna ^b   Gonzini, Lucio ^b   Caruso, Davide ^a   Fontanella, Andrea ^c   Pellegrini, Francesco ^d   Silvestri, Nunzia ^e   Vincenti, Antonio ^f   Mathieu, Giovanni ^g   Di Pasquale, Giuseppe ^h  

^a Padre Antero Micone Hospital   (Italy)

^b ANMCO RESEARCH CENTER   (Italy)

^c Department of Internal Medicine Buon Consiglio FBF Hospital   (Italy)

^d Department of Internal Medicine Presidio Ospedaliero ^*  (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g Pinerolo Hospital   (Italy)

^h MAGGIORE HOSPITAL   (Italy)

Author keywords

antiarrhythmic agents; atrial fibrillation; rate control; rhythm control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DIGITALIS; DILTIAZEM; FLECAINIDE; PROPAFENONE; SOTALOL; VERAPAMIL; FIBRINOLYTIC AGENT;

AGED; ARTICLE; CARDIOLOGIST; CARDIOVERSION; CLINICAL PRACTICE; COMORBIDITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERNIST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; VERY ELDERLY; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPLICATION; CORONARY CARE UNIT; DRUG COMBINATION; INTERNAL MEDICINE; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROSPECTIVE STUDY; STANDARDS; STATISTICS AND NUMERICAL DATA; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOLOGY SERVICE, HOSPITAL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 84903818592     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000110     Document Type: Article

References (26)

1. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840. (Pubitemid 35417774)
2. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833. (Pubitemid 35417773)
3. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000; 356:1789-1794.
4. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs. rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005; 165:258-262. (Pubitemid 40216276)
5. Chung M K, Shemanski L, Sherman DG, et al. AFFIRM Investigators. Functional status in rate versus rhythm control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) function al status substudy. J Am Coll Cardiol 2005; 46:1891-1899. (Pubitemid 41579813)
6. Carlsson J Miketic S Windeler J et al STAF Investigators. Randomized trial of rate control versus rhythm control in persistent atria l fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study J Am Coll Cardiol 2003 41 1690-1696. (Pubitemid 36584236)
7. Opolski G, Torbicki A, Kosior DA, et al. Investigators of the Polish How t o treat Chronic Atrial Fibrillation Study. Rate control versus rhythm control in patients with non valvular persistent atrial fibrillation: the results of the Polish How to treat Chronic Atrial Fibrillation (HOT-CAFÉ ) study. Chest 2004; 126:476-486. (Pubitemid 39093433)
8. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). E ur Heart J 2010; 31:2369-2429.
9. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010; 375:1212-1223.
10. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atiral Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 1 59:340-347; e1.
11. Connolly SJ, Ezekowitz MD, Jusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
12. Tsadok MA, Jackevicius CA, Essebag V, et al. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation 2012; 126:2680-26 87.
13. Nieuwlat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27:3 018-3026. (Pubitemid 44963431)
14. Zoni Berisso M, Filippi A, Landolina M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Manageme nt [ISAF] Study). Am J Cardiol 2013; 111:705-711.
15. Go AS, Hyleck EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibri llation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-934. (Pubitemid 30005032)
16. Di Pasquale G, Mathieu G, Maggioni AP, et al. Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA-AF study. Int J Cardiol 2013; 167:2895-2903.
17. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NTEwork on Atrial Fibrillation: patients characteristics and initial management. Europace 2009 ; 11:423-434.
18. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26:2422-2434. (Pubitemid 41552972)
19. Bungard TJ, GHali WA, Teo KR, McAlister FA, Tsuyuki RT. Why do patient with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160:41-46. (Pubitemid 30040971)
20. McCabe JM, Johnson CJ, Marcus GM. Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation. Am J Cardiol 2009; 103:535-539.
21. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J 2006; 151:771-778.
22. Dorian P, Guerra PG, Kerr CR, et al. Validation of a ne w simple scale to measure symptoms in atrial fibrillation. The Canadian Cardiovascular Society Severity in Atrial Fibrillation Scale. Circ Arrhythm Electrophysiol 2009; 2:218-224.
23. Santini M, De Ferrari GM, Pandozi C, et al. Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from the atrial Fibrillation/flutter Italian Registry (FIRE). Ital Heart J 2004; 5:2 05-213.
24. La Pointe NMA, Sun JL, Kaplan S, d'Almada P, Al-Khatib SM. Rhythm versus rate control in the contemporary management of atrial fibrillation inhospital. Am J Cardiol 2008; 101:1134-1141.
25. Le Heuzy JY, Breithardt G, Camm J, et al. The RecordAF Study: design, baseline data and profile of patients according to the chosen treatment strategy for atrial fibrillation. Am J Cardiol 2010; 105:687-693.
26. Reiffel JA, Kowe PR, Myeburg R, et al. AFFECTS Scientific Advisory Committee and Investigators. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry) . Am J Cardiol 2010; 105:1122- 1129.